Skip to main
SUPN
SUPN logo

Supernus Pharmaceuticals (SUPN) Stock Forecast & Price Target

Supernus Pharmaceuticals (SUPN) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 9%
Hold 45%
Sell 0%
Strong Sell 0%

Bulls say

Supernus Pharmaceuticals Inc. holds significant market opportunities with products like Qelbree for ADHD, which is poised for growth due to its unique non-stimulant characteristics and strong clinical data, with projected sales exceeding $600 million. The company also benefits from a two-year patent extension for Qelbree until 2035, providing additional protection and potential for sustained revenue. Furthermore, Supernus’s robust balance sheet enables it to pursue acquisitions valued between $500 million to $1.5 billion, allowing for strategic expansion within its market.

Bears say

Supernus Pharmaceuticals is facing a negative outlook due to disappointing Phase 2b data from its SPN-820 trial for treatment-resistant depression, prompting a downgrade from an optimistic position. The company's market potential could be diluted by challenges in commercial execution, compounded by inherent clinical trial risks that may hinder regulatory approvals for new or expanded indications. Additionally, clinicians' reluctance to alter prescribing practices based on their experiences with existing therapies further threatens the adoption of Supernus's products, potentially impacting sales and growth.

Supernus Pharmaceuticals (SUPN) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 9% recommend Buy, 45% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Supernus Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Supernus Pharmaceuticals (SUPN) Forecast

Analysts have given Supernus Pharmaceuticals (SUPN) a Buy based on their latest research and market trends.

According to 11 analysts, Supernus Pharmaceuticals (SUPN) has a Buy consensus rating as of Aug 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Supernus Pharmaceuticals (SUPN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.